Luspatercept for Anemia Post-Allo-HSCT in Blood Disorder Patients
Overview
Luspatercept demonstrated significant efficacy in improving hemoglobin levels in 16 patients with anemia following allogeneic hematopoietic stem cell transplantation (allo-HSCT), with 81.3% achieving erythroid response. The treatment was well tolerated with only mild, transient adverse effects reported.
Background
Anemia is a frequent complication after allo-HSCT, caused by immune and non-immune factors such as autoimmune hemolytic anemia and pure red cell aplastic anemia (PRCA). Conventional immunosuppressive treatments carry risks of infection, highlighting the need for safer alternatives. Luspatercept, an activin receptor fusion protein, promotes late-stage erythroblast differentiation and is FDA-approved for certain anemias but its role post-allo-HSCT was previously unclear. This retrospective study evaluated luspatercept's efficacy and safety in patients with anemia after allo-HSCT.
Data Highlights
Parameter
Before Luspatercept
After Luspatercept
p-value
Mean Hemoglobin (g/L)
58.9 (43–71)
82.9 (55–114)
<0.0001
Mean Neutrophil Count (×10⁹/L)
1.7 (0.35–6.1)
2.2 (0.39–4.76)
0.26
Median Platelet Count (×10⁹/L)
22.5 (3–141)
37 (5–178)
0.13
Key Findings
Thirteen of 16 patients (81.3%) achieved erythroid response after luspatercept treatment, with a median time to response of 7 days.
Four responders (30.8%) remained transfusion-independent at last follow-up.
Luspatercept significantly increased mean hemoglobin levels from 58.9 to 82.9 g/L (p < 0.0001).
No significant changes were observed in neutrophil or platelet counts post-treatment.
Adverse events were mild (grade 1 fatigue, palpitations, limb edema) and resolved spontaneously within one week.
Overall survival at median 325 days follow-up was 93.8%, with one death unrelated to luspatercept.
Clinical Implications
Luspatercept offers a promising therapeutic option for managing anemia following allo-HSCT, particularly in patients with poor graft function or PRCA, by effectively increasing hemoglobin levels and reducing transfusion dependence. Its favorable safety profile and minimal impact on neutrophil and platelet counts make it a viable alternative to immunosuppressive therapies that carry higher infection risks. Clinicians should consider luspatercept as part of anemia management strategies post-transplantation.
Conclusion
This retrospective study supports luspatercept as an effective and safe treatment for anemia after allo-HSCT, improving erythroid parameters with minimal toxicity. Further prospective studies are warranted to confirm these findings and optimize treatment protocols.
References
Luspatercept in the Management of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Blood Disorders
Luca Stocchi, M.D., a colorectal surgeon at Mayo Clinic in Florida, presents a surgical case involving a 53-year-old male with long-standing, fistulizing Crohn's disease. The patient had a prior open ileocolic resection and subsequently developed progressive weight loss and anemia.
